Uppsala, Sweden – November 22, 2017 – Orexo AB (publ.) (the “Company”) today announces that the Company, in accordance with Orexo’s press release on 31 October 2017, has completed the early total redemption of the existing bond loan (ISIN SE0005932159).
The redemption was made at an amount corresponding to 101 percent of the nominal amount (i.e. SEK 1,010,000 per bond, the nominal amount being SEK 1,000,000) together with accrued but unpaid interest from the preceding interest payment date on November 9 2017 up to, and including, the redemption date on November 22 2017. In conjunction herewith, the bonds are delisted from the corporate bond list of Nasdaq Stockholm.
For further information, please contact:
|Orexo AB (publ.)|
Nikolaj Sørensen, President and CEO
Tel: +46 (0)18 780 88 00
Henrik Juuel, EVP and CFO
Tel: + 46 (0)18 780 88 00
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites www.zubsolv.com and www.rise-us.com.
The information was submitted for publication at 8:30 am CET, November 22, 2017